Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906071 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 577
- Enrollment target
NCT03906071 is a Phase 3 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 577 participants.
The verdict
NCT03906071, a Phase 3 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 577 participants
- Enrollment target
Study Summary
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 577 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03906071
The ClinicalTrials.gov registry entry for NCT03906071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 577 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT03906071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03906071 about?
NCT03906071 is a clinical study titled "Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer". This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
What is the current status of trial NCT03906071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 577 participants. The study started on 2019-07-15. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT03906071?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (BIOLOGICAL), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT03906071?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.